Zhongmei

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Zhongmei Huadong) is a leading Chinese pharmaceutical company and the core subsidiary of Huadong Medicine. The company is a major player in the fields of oncology, endocrinology, immunology, and medical aesthetics, with a strong focus on innovative drug development and high-end generics. Zhongmei Huadong has established a diverse pipeline through internal R&D and strategic global partnerships, featuring advanced modalities such as antibody-drug conjugates (ADCs), GLP-1 receptor agonists, and CAR-T cell therapies. Key products include the FRα-targeting ADC Elahere (mirvetuximab soravtansine) and the GLP-1 receptor agonist liraglutide. The company maintains a robust manufacturing and commercialization infrastructure, positioning it as a central hub for pharmaceutical innovation in China.